Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (131-140 of 247) with videos related to

Pageof 25
Sort By:
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan and temozolomide in patients with solid tumorsSuzanne F Jones, Victor G Gian, F Anthony Greco, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2011
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumoursPatrick Schöffski, Suzanne F Jones, Herlinde Dumez, et al.
Clinical Advances in Hematology & Oncology : H&O|September 25, 2010
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancerDavid R Spigel, F Anthony Greco, David Waterhouse, et al.
JAMA Oncology|February 10, 2018
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 StudyDaniel P Petrylak, Thomas Powles, Joaquim Bellmunt, et al.
Cancer Journal (Sudbury, Mass.)|August 20, 2002
Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Anthony A Meluch, Suzanne McClurkan, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsAnne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Ian W Flinn, David R Spigel, et al.
Pageof 25

Showing results (131-140 of 247) with videos related to

Sort By:
Pageof 25
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan and temozolomide in patients with solid tumorsSuzanne F Jones, Victor G Gian, F Anthony Greco, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2011
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumoursPatrick Schöffski, Suzanne F Jones, Herlinde Dumez, et al.
Clinical Advances in Hematology & Oncology : H&O|September 25, 2010
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancerDavid R Spigel, F Anthony Greco, David Waterhouse, et al.
JAMA Oncology|February 10, 2018
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 StudyDaniel P Petrylak, Thomas Powles, Joaquim Bellmunt, et al.
Cancer Journal (Sudbury, Mass.)|August 20, 2002
Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Anthony A Meluch, Suzanne McClurkan, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsAnne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Ian W Flinn, David R Spigel, et al.
Pageof 25